AAAAAA

   
Results: 1-9 |
Results: 9
Cytokines in cervicovaginal washing fluid from patients with cervical neoplasia
Authors: Tjiong, MY van der Vange, N ter Schegget, JS Burger, MPM ten Kate, FWJ Out, TA
Citation: My. Tjiong et al., Cytokines in cervicovaginal washing fluid from patients with cervical neoplasia, CYTOKINE, 14(6), 2001, pp. 357-360
D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTCgynaecological cancer co-operative group study
Authors: Duffaud, F van der Burg, MEL Namer, M Vergote, I Willemse, PHB Huinink, WT Guastalla, JP Nooij, MA Kerbrat, P Piccart, M Tumolo, S Favalli, G van der Vange, N Lacave, AJ Wils, J Splinter, TAW Einhorn, N Roozendaal, KJ Rosso, R Vermorken, JB
Citation: F. Duffaud et al., D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTCgynaecological cancer co-operative group study, ANTI-CANC D, 12(2), 2001, pp. 159-162
A mathematical evaluation of dose-dependent PpIX fluorescence kinetics in vivo
Authors: Aalders, MCG van der Vange, N Star, WM Sterenborg, HJCM
Citation: Mcg. Aalders et al., A mathematical evaluation of dose-dependent PpIX fluorescence kinetics in vivo, PHOTOCHEM P, 74(2), 2001, pp. 311-317
IgG antibodies against human papillomavirus type 16 E7 proteins in cervicovaginal washing fluid from patients with cervical neoplasia
Authors: Tjiong, MY Ter Schegget, J Tjong-A-Hung, SP Out, TA van der Vange, N Burger, MPM Struyk, L
Citation: My. Tjiong et al., IgG antibodies against human papillomavirus type 16 E7 proteins in cervicovaginal washing fluid from patients with cervical neoplasia, INT J GYN C, 10(4), 2000, pp. 296-304
Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot
Authors: van der Vange, N van Goethem, AR Zoetmulder, FAN Kaag, MM van de Vaart, PJM Huinink, WWT Beijnen, JH
Citation: N. Van Der Vange et al., Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot, EUR J SUR O, 26(7), 2000, pp. 663-668
Photodetection with 5-aminolevulinic acid-induced protoporphyrin IX in therat abdominal cavity: Drug-dose-dependent fluorescence kinetics
Authors: Aalders', MCG Sterenborg, HJCM Stewart, FA van der Vange, N
Citation: Mcg. Aalders' et al., Photodetection with 5-aminolevulinic acid-induced protoporphyrin IX in therat abdominal cavity: Drug-dose-dependent fluorescence kinetics, PHOTOCHEM P, 72(4), 2000, pp. 521-525
Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix
Authors: de Gruijl, TD Bontkes, HJ van den Muysenberg, AJC van Oostveen, JW Stukart, MJ Verheijen, RHM van der Vange, N Snijders, PJF Meijer, CJLM Walboomers, JMM Scheper, RJ
Citation: Td. De Gruijl et al., Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix, EUR J CANC, 35(3), 1999, pp. 490-497
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer
Authors: Herben, VMM Panday, VRN Richel, DJ Schellens, JHM van der Vange, N Rosing, H Beusenberg, FD Hearn, S Doyle, E Beijnen, JH Huinink, WWT
Citation: Vmm. Herben et al., Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer, J CL ONCOL, 17(3), 1999, pp. 747-755
Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer
Authors: Tjiong, MY van der Vange, N ten Kate, FJW Tjong-A-Hung, SP ter Schegget, J Burger, MPM Out, TA
Citation: My. Tjiong et al., Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer, GYNECOL ONC, 73(2), 1999, pp. 285-291
Risultati: 1-9 |